Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5OJT

Structure-Activity Relationships and Biological Characterization of a Novel, Potent and Serum Stable C-X-C chemokine receptor type 4 (CXCR4) Antagonist

5OJT の概要
エントリーDOI10.2210/pdb5ojt/pdb
NMR情報BMRB: 34165
分子名称ACE-ARG-ALA-(D)CYS-ARG-BNA-HIS-PEN (1 entity in total)
機能のキーワードcxcr4, peptide binding protein
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数1
化学式量合計999.24
構造登録者
Brancaccio, D.,Carotenuto, A. (登録日: 2017-07-24, 公開日: 2017-11-22, 最終更新日: 2023-11-15)
主引用文献Di Maro, S.,Di Leva, F.S.,Trotta, A.M.,Brancaccio, D.,Portella, L.,Aurilio, M.,Tomassi, S.,Messere, A.,Sementa, D.,Lastoria, S.,Carotenuto, A.,Novellino, E.,Scala, S.,Marinelli, L.
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.
J. Med. Chem., 60:9641-9652, 2017
Cited by
PubMed Abstract: In our ongoing pursuit of CXCR4 antagonists as potential anticancer agents, we recently developed a potent, selective, and plasma stable peptide, Ac-Arg-Ala-[d-Cys-Arg-Phe-Phe-Cys]-COOH (3). Nevertheless, this compound was still not potent enough (IC ≈ 53 nM) to enter preclinical studies. Thus, a lead-optimization campaign was here undertaken to further improve the binding affinity of 3 while preserving its selectivity and proteolytic stability. Specifically, extensive structure-activity relationships (SARs) investigations were carried out on both its aromatic and disulfide forming amino acids. One among the synthesized analogue, Ac-Arg-Ala-[d-Cys-Arg-Phe-His-Pen]-COOH (19), displayed subnanomolar affinity toward CXCR4, with a marked selectivity over CXCR3 and CXCR7. NMR and molecular modeling studies disclosed the molecular bases for the binding of 19 to CXCR4 and for its improved potency compared to the lead 3. Finally, biological assays on specific cancer cell lines showed that 19 can impair CXCL12-mediated cell migration and CXCR4 internalization more efficiently than the clinically approved CXCR4 antagonist plerixafor.
PubMed: 29125295
DOI: 10.1021/acs.jmedchem.7b01062
主引用文献が同じPDBエントリー
実験手法
SOLUTION NMR
構造検証レポート
Validation report summary of 5ojt
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon